During Wednesday’s Current trade, Shares of BlackRock, Inc. (NYSE:BLK), gain 0.79% to $345.32.
With U.S. monetary policy turning, fundamentals such as productivity and earnings growth are poised to regain prominence as drivers of investment return - with some key indicators “flashing red,” according to BlackRock (BLK) Investment Institute’s (BII) mid-year 2015 investment outlook.
The mid-year outlook, “Nearing Normal,” provides an update on BII’s main economic assumptions and top investment ideas for 2015, a year so far characterized by divergence in global central bank monetary policy and asset prices.
BlackRock, Inc. is a publicly owned investment manager. The firm primarily provides its services to institutional, intermediary, and individual investors. It also manages accounts for corporate, public, union and industry pension plans, insurance companies, third-party mutual funds, endowments, foundations, charities, corporations, official institutions, and banks.
Shares of Cimarex Energy Co (NYSE:XEC), declined -0.50% to $108.43, during its current trading session.
Cimarex Energy Co. (XEC) declared that it plans to report second quarter 2015 financial results after market close on Tuesday, August 4, 2015. The company will host its quarterly conference call at 11:00 AM EDT on Wednesday, August 5, 2015.
Cimarex Energy Co. operates as an independent oil and gas exploration and production company primarily in Texas, Oklahoma, and New Mexico. The company owns interests in 3,240 net productive oil and gas wells. As of December 31, 2014, it had a total proved oil and gas reserves of 3.1 trillion cubic feet equivalent (Tcfe) comprising of 1.7 trillion cubic feet of natural gas; and 0.7 Tcfe each of oil and natural gas liquids primarily located in the Permian Basin and Mid-Continent regions.
Kite Pharma Inc (NASDAQ:KITE), during its Wednesday’s current trading session gained 4.56% to $72.97.
Kite Pharma, Inc. (KITE) and bluebird bio, Inc. (BLUE) declared that they have reached a partnershipagreement to co-develop and co-commercialize second generation T cell receptor (TCR) product candidates directed against the human papillomavirus type 16 E6 (HPV-16 E6) oncoprotein incorporating gene editing and lentiviral technologies. bluebird bio has a platform comprised of lentiviral gene delivery and gene editing capabilities, with a focus on rare diseases and cancer immunotherapies. Kite has a broad existing pipeline of TCR product candidates and will continue to develop its existing and wholly-owned TCR programs directed against high-risk HPV, which are unaffected by this collaboration, counting HPV-16 E6 TCR, presently in a Phase I study, and HPV-16 E7 TCR. The partnership brings together the powerful technologies and capabilities of these two leading immunotherapy companies.
Under the terms of the agreement, both companies will jointly develop and commercialize second generation TCR product candidates directed against the HPV-16 E6 oncoprotein, incorporating gene editing to efficiently modify certain genes to enhance T cell function. In addition, the companies will explore using lentiviral vectors to optimize delivery of HPV-16 E6 TCRs into patient T cells.
Kite will lead the program in the U.S., and bluebird bio will have the option to lead the program in the European Union. Both companies will share overall costs, counting research and development and sales and marketing expenses, and profits will be equally split between the companies. Additionally, Kite will have a co-promotion option in the European Union, and bluebird will have a co-promotion option in the U.S.
Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate is KTE-C19, a chimeric antigen receptors (CAR)-based therapy that is in Phase 1-2a clinical trials for the treatment of patients with refractory diffuse large B cell lymphoma. The company is also developing T cell receptors-based therapies, which targets SSX2, NY-ESO-1, and MAGE antigens in various cancers.
Finally, Popular Inc (NASDAQ:BPOP), gained 1.14%, to $29.34.
Popular Inc (BPOP) declared that it anticipates to report its financial results for the second quarter ending June 30, 2015 before the market opens on Friday, July 24, 2015.
Popular will hold a conference call to talk about the financial results the same day at 10:00 a.m. Eastern Time. The call will be broadcast live over the Internet and can be accessed through the investor relations section of the Corporation’s website: www.popular.com.
Popular, Inc., through its auxiliaries, provides various retail and commercial banking products and services primarily to institutional and retail customers. The company accepts various deposit products. It also offers commercial and industrial loans; commercial real estate loans; construction loans; lease financing comprising automobile loans/leases; residential mortgage and construction loans; and consumer loans, counting personal loans, credit cards, home equity lines of credit, and other loans to individual borrowers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
